A wide range of potential enablers and barriers were identified for influencing progress for the scale-up of severe wasting services within national health systems. Findings were categorised according to the six pillars of WHO’s health system strengthening framework.
Interim Guidance October 2022. This addendum addresses some of the methodological aspects of VE evaluations that have been learned during the past year, as well as those that have become relevant in the current epidemiological setting of the COVID-19 pandemic. For some of the COVID-19 vaccine method...ology issues there are still insufficient data to make a recommendation, in which case different options for approaching VE evaluations are presented.
more
The 2020 recommendations for the programmatic management of TB preventive treatment are the first to be released under the rubric of WHO consolidated TB guidelines (Module 1 – Prevention). The WHO consolidated TB guidelines will gradually group all TB recommendations and will be complemented by ma...tching modules of a consolidated operational handbook. [1] The handbook will provide practical advice on how to put in place the recommendations at the scale needed to achieve national and global impact. The first handbook module in the series will be on the programmatic management of TB preventive treatment and will accompany the 2020 guidelines.
more
The WHO operational handbook on tuberculosis: tuberculosis preventive treatment is the companion, implementation guide to the 2020 WHO guidelines on TB preventive treatment.[1] Just as these guidelines are the first to be released under the rubric of the WHO consolidated TB guidelines, this handbook... will be the first in a modular series of practical guides meant for the implementers of various aspects of the programmatic management TB.
more
: interim guidance, 17 February 2021
This document provides interim guidance on the management of the blood supply in response to the pandemic outbreak of coronavirus disease (COVID-19). It emphasizes the importance of being prepared and responding quickly and outlines key actions and measures that... the blood services should take to mitigate the potential risk to the safety and sufficiency of the blood supplies during the pandemic.
It should be read in conjunction with WHO Guidance for National Blood Services on Protecting the Blood Supply During Infectious Disease Outbreaks, which provides general guidance on the development of national plans to respond to any emerging infectious threats to the sufficiency or safety of the blood supply.
more
based on information as at 28 February 2021
Rapid Policy Brief Series Series 14: COVID-19 and hypertension
COVID-19 Vaccines: 1 Safety Surveillance 2 Manual
While there is no indication that pregnant women have an increased susceptibility to infection with SARS-CoV-2, there is evidence that pregnancy may increase the risk of severe illness and mortality from COVID-19 disease in comparison with non-pregn...ant women of reproductive age. As seen with non-pregnant women, a high proportion of pregnant women have asymptomatic SARS-CoV-2 infection and severe disease is associated with recognized medical (e.g., high body-mass index (BMI), diabetes, pre-existing pulmonary or cardiac conditions) and social (e.g., social deprivation, ethnicity) risk factors. Pregnant women with symptomatic COVID-19 appear to have an increased risk of intensive care unit admission, mechanical ventilation and death in comparison with non-pregnant women of reproductive age, although the absolute risks remain low. COVID-19 may increase the risk of preterm birth, compared with pregnant women without COVID-19, although the evidence is inconclusive.
more
29 Dec 2021. Comprehensive slideset updated regularly to include the latest data and guidance on best practices for COVID-19 diagnosis and prevention of COVID-19 transmission.
Licensed pharmaceutical products (marketing authorization) should be manufactured only by licensed manufacturers (holders of a manufacturing authorization) whose activities are regularly inspected by competent national authorities. This guide to GMP shall be used as a standard to justify GMP status,... which constitutes one of the elements of the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce, through the assessment of applications for manufacturing authorizations and as a basis for the inspection of manufacturing facilities. It may also be used as training material for government medicines inspectors, as well as for production, QC and QA personnel in the industry
more
Available in Chinese, English, French, Russian and Spanish; WHO and UNICEF policy brief, 19 April 2021
Persons with disabilities are disproportionately impacted by COVID-19, both directly because of infection, and indirectly because of restrictions to reduce the spread of the virus. Persons with di...sabilities are a diverse group, and the risks, barriers and impacts faced by them will vary in different contexts according to, among other factors, their age, gender identity, type of disability, ethnicity, sexual orientation, and migration status.
This document presents considerations and actions for the following stakeholders to ensure equity in access to vaccination against COVID‑19 for persons with disabilities
more
Der Policy Brief des Kompetenznetz Public Health COVID-19 befasst sich mit der empirischen Evidenz zu SARS-Cov-2 bei Migrant*innen und geflüchteten Menschen und leitet hieraus Handlungsempfehlungen ab. Eine Kernbotschaft des Papiers ist, dass das Risiko von SARS-CoV-2 Neuinfektionen unter Migrant*i...nnen im Vergleich zu Nicht-Migrant*innen höher ist, Krankenhauseinweisungen hingegen seltener sind.
more